& Kat, i'll add a re-thought.....

I've said / asked ---- how would an ICI mfgr benefit from directly investing into Cytodyn, with market dosing being physicians choice ??

Only thing I can / could see is --- once proven your ICI works with LL, the ICI would buy in advance a supply of LL.

& if, if our mTNBC PD-L1 protocol does go multiple ICI's, that justifies the above thought....

Including Cytodyn watches the ICI industry foot the bulk billing on expanding their already sales & marketing to now include the LL combos for us.

If Cytodyn does go multiple subtype tumors & simply re-doses the same patients, those thoughts look like a seriously real potential.

( not to mention already having our patient pool )

ICI mfgr's push combo awareness --- Cytodyn stays lean, mean profit machine.

& again, no need for a GSK level of 60k+ employees & etc.

Of course including your past comments of Cytodyn still needing legal expansion & other certain departments.

But would be an all around outstanding position for Cytodyn